Helicobacter pylori infection, hyperuricemia, and serum uric acid levels: The role of metabolic, renal, and inflammatory factors in a large health examination population Authors: Zhiyue Xu, Xiuyu Wang, Jie Huang, Chunxing Liu, Yong Fang, Emily Chenette, Ahmed Abdel Moneim, Ahmed Abdel Moneim Published: 2026 ABSTRACT BackgroundHelicobacter pylori (H. pylori) infection has been linked to several extragastric metabolic disorders. However, its cross-sectional association with hyperuricemia remains uncertain, partly because previous studies have often been limited by small sample sizes and incomplete adjustment for metabolic and renal factors.MethodsThis large-scale cross-sectional study used data from a health examination database. The main regression analyses included 67,826 participants with valid H. pylori status, serum uric acid measurements, hyperuricemia classification, age, sex, and BMI. Modified Poisson regression with a log link and HC0 robust sandwich variance was used to estimate prevalence ratios for hyperuricemia, while linear regression with HC3 heteroscedasticity-robust standard errors was used for continuous serum uric acid. Sex-stratified and robustness analyses were also performed.ResultsIn the unadjusted model, H. pylori infection was associated with higher prevalence of hyperuricemia (PR = 1.27, 95% CI: 1.22–1.32, p < 0.001). This association was progressively attenuated after sequential adjustment and was small in the extended clinical model (PR = 1.02, 95% CI: 0.98–1.06, p = 0.269). For continuous serum uric acid, H. pylori positivity remained associated with a small increase after full adjustment (β = 2.14 μmol/L, 95% CI: 0.80–3.49, p = 0.002). Functional-form sensitivity analyses yielded similarly small effect estimates for hyperuricemia, although statistical significance varied across model specifications. Sex-stratified and robustness analyses were generally consistent with these findings.ConclusionIn this large health examination population, any remaining association between H. pylori positivity and hyperuricemia after comprehensive adjustment was small and sensitive to model specification. H. pylori positivity was also associated with a statistically detectable but clinically modest difference in continuous serum uric acid levels. Given the cross-sectional design, these findings should not be interpreted causally. 1. Introduction Helicobacter pylori (H. pylori) infection is one of the most common chronic bacterial infections worldwide and is well established as a major cause of chronic gastritis, peptic ulcer disease, and gastric cancer [1]. In addition to its gastric manifestations, H. pylori infection has been investigated in relation to several extragastric conditions, including metabolic abnormalities, low-grade systemic inflammation, and cardiometabolic risk [2]. Observational studies and meta-analyses have suggested that H. pylori infection may be associated with metabolic syndrome and insulin resistance, although the evidence remains inconsistent across populations [3]. The substantial heterogeneity reported in previous studies suggests that these associations may depend on population characteristics, clinical background, and the extent to which metabolic and inflammatory confounders are controlled [3]. Hyperuricemia is a common metabolic abnormality and represents the key biochemical basis of gout. It is also closely linked to obesity, insulin resistance, elevated blood pressure, impaired renal function, and cardiometabolic disease risk [4,5]. Serum uric acid homeostasis is determined by the balance between urate production and excretion, with renal excretion playing a central role in maintaining circulating uric acid levels [6]. Experimental and clinical studies have shown that insulin resistance and hyperinsulinemia can reduce renal uric acid excretion and promote urate reabsorption, thereby contributing to hyperuricemia [7,8]. Renal tubular urate transporters, including URAT1 and GLUT9, are also critical regulators of urate reabsorption and serum uric acid homeostasis [6,9]. Therefore, if H. pylori infection is intertwined with insulin resistance, chronic inflammation, or renal functional changes, it may plausibly be associated with serum uric acid levels and hyperuricemia. However, the adjusted cross-sectional association between H. pylori infection and abnormalities in uric acid metabolism remains uncertain. Some observational studies have reported that H. pylori infection is associated with higher serum uric acid levels or a greater burden of uric acid–related outcomes, whereas others suggest that these associations may be substantially attenuated after adjustment for metabolic and renal factors [10,11]. Chen et al. reported a positive association between H. pylori infection and gout among Chinese adults with hyperuricemia, whereas Wang et al. observed higher serum uric acid levels in crude comparisons but no significant overall association after multivariable adjustment, with evidence of effect modification by renal function [10,11]. Our study extends this literature by examining both hyperuricemia and continuous serum uric acid in a substantially larger health-examination population with detailed renal and metabolic adjustment and functional-form sensitivity analyses. In this context, the present study used data from a large health examination population to systematically evaluate the cross-sectional associations of H. pylori infection with hyperuricemia and continuous serum uric acid levels. Using sequentially adjusted models, we examined the extent to which demographic factors, BMI, blood pressure, glucose and lipid metabolism, renal function, liver enzymes, and systemic inflammatory markers accounted for these associations. We also performed sex-stratified analyses and multiple robustness analyses to assess the consistency and clinical relevance of the observed cross-sectional associations between H. pylori infection and abnormalities in uric acid metabolism. 2. Methods 2.1. Study design and Data Source This retrospective cross-sectional study was approved by the Ethics Committee of Shanghai Health and Medical Center (approval number: (2026) No. 5; approval date: March 2, 2026) and used deidentified routine health-examination records maintained by Shanghai Health and Medical Center, Wuxi, Jiangsu Province, China. The study was conducted in accordance with the Declaration of Helsinki. The present secondary analysis was confirmed to fall within the scope of the approved deidentified health examination dataset. The study period extended from October 1, 2024, to October 31, 2025, and the deidentified dataset was accessed for research purposes on May 21, 2026. The requirement for informed consent was waived because this was a retrospective analysis of deidentified data. Participants were identified using an anonymized personal identifier to avoid duplicate inclusion of repeated examinations; for participants with more than one health examination record during the study period, only the most recent valid examination record was retained to construct an individual-level analytical dataset. The authors did not have access to direct personal identifiers during or after data collection. 2.2. Study Population The original database contained 109,329 health examination records. After restricting the records to the study period, 106,345 records remained. One non-qualifying examination record with essentially unavailable examination measurements was excluded before participant-level deduplication, leaving 106,344 valid study-period records. For participants with repeated examinations, only the most recent valid examination record was retained, yielding 97,378 unique participants. We then excluded 24,811 participants with missing H. pylori test results and, among the remaining participants, 175 with missing serum uric acid measurements, leaving 72,392 participants for the baseline analyses. After excluding 4,566 participants with missing BMI, 67,826 participants remained for the main regression analyses; no participants were excluded because of missing age or sex at this stage (Fig 1). Flow diagram of participant selection. 2.3. Definition of H. pylori Infection H. pylori infection status was determined using the fasting 13C-urea breath test (13C-UBT), which was routinely performed as part of health-examination services at the study center rather than specifically administered for this study. Participants undergoing testing fasted for at least 8 h. A baseline (0-min) breath sample was collected by exhaling through a straw into a sample bag for approximately 4–5 s. Participants then ingested 75 mg of 13C-urea granules (Beijing Boran Pharmaceutical Co., Ltd., Beijing, China) with 80 mL of cool water and remained seated for 30 min, after which a second breath sample was collected using the same procedure. Breath samples were analyzed using a HY-IREXplus breath analyzer (Jiangxi Xinyu Lian’er Medical Technology Co., Ltd., Jiangxi, China). Routine instrument self-checks were performed in accordance with the analyzer operating procedures. Results were expressed as delta over baseline (DOB), calculated as the difference between the 30-min and baseline measurements. In accordance with the manufacturer’s recommended decision threshold, a DOB ≥ 4.0 was classified as H. pylori positive and a DOB < 4.0 as negative. Participants without an available H. pylori test result were excluded from the corresponding analyses. 2.4. Definition of Serum Uric Acid and Hyperuricemia Serum uric acid was analyzed as a continuous outcome. Hyperuricemia was analyzed as the primary binary outcome and was defined using conventional sex-specific epidemiological thresholds of serum uric acid >420 μmol/L in men and >360 μmol/L in women [12]. 2.5. Laboratory Measurements After an overnight fast of 8–12 h, venous blood samples were collected during the health examinations. Serum biochemical measurements, including uric acid, fasting glucose, lipid parameters, liver enzymes, creatinine, and hs-CRP, were performed on a Roche cobas 8000 analytical platform (c702 chemistry module; Roche Diagnostics) using manufacturer-matched Roche reagents. Serum uric acid was measured using a uricase/peroxidase enzymatic colorimetric method, fasting glucose using a hexokinase UV method, triglycerides using an enzymatic colorimetric LPL/GK/GPO/POD method, and HDL-C using a homogeneous enzymatic colorimetric method. ALT and AST were measured using IFCC-traceable kinetic UV methods based on LDH- and MDH-coupled NADH oxidation, respectively; serum creatinine was measured using an enzymatic creatinine method, and GGT using an enzymatic colorimetric rate method. White blood cell count and hemoglobin were measured using a BC-6800Plus automated hematology analyzer on a CAL 8000Plus line (Mindray Bio-Medical Electronics, Shenzhen, China). WBC counting and classification were based on laser scattering with fluorescent staining flow cytometry, whereas hemoglobin was measured using a colorimetric absorbance method. Routine calibration and internal quality-control procedures were performed in accordance with laboratory standard operating procedures and manufacturer instructions. 2.6. Covariates Covariates were selected by clinical domain, prior epidemiological evidence, measurement availability, parsimony, and avoidance of redundant correlated measures; selection was not based on p values or stepwise procedures. The basic adjustment model included age, sex, and BMI. BMI was used as the primary general adiposity measure, so waist circumference was not simultaneously entered. The metabolic adjustment model further included systolic blood pressure, fasting blood glucose, triglycerides, and HDL-C. SBP was used as the principal blood-pressure indicator, so DBP was not simultaneously entered. FBG was used as the primary routinely available glycemic measure because HbA1c had greater missingness and was not required for the primary model. The extended clinical model additionally included eGFR, ALT, GGT, and WBC. ALT and GGT were included as complementary hepatic/metabolic indicators, whereas AST was not simultaneously included to limit redundant liver-enzyme adjustment. The sequential adjustment framework was based on clinical domains and available epidemiological evidence; additional assumption and robustness analyses were conducted to examine model assumptions. HDL-C, liver enzymes, renal function indices, and WBC were treated as available clinical indicators reflecting metabolic, hepatic, renal, and inflammatory status. However, these variables could not fully replace direct information on diet, alcohol intake, smoking, physical activity, or medication use. Medication use, including urate-lowering agents, diuretics, antibiotics, proton pump inhibitors, and bismuth-containing medications, was not used as an exclusion criterion because individual-level medication information was not available in the retrospective database. eGFR was calculated using the 2021 race-free Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation, which incorporates serum creatinine, age, and sex. Serum creatinine values were converted from μmol/L to mg/dL before calculation [13]. Because hs-CRP had substantial missingness, it was not included in the primary extended clinical model and was evaluated only in a sensitivity analysis among participants with available hs-CRP data. 2.7. Statistical Analysis The distribution of continuous variables was assessed using histograms, Q-Q plots, and the Kolmogorov–Smirnov test. Approximately normally distributed variables were summarized using means ± standard deviations and compared using Welch’s t test. Markedly skewed variables were summarized using medians and interquartile ranges (IQRs) and compared using the Mann–Whitney U test. Categorical variables were summarized as n (%) and compared using the chi-square test. Absolute standardized mean differences (SMDs) were calculated for baseline comparisons; continuous SMDs used the difference in group means divided by the pooled standard deviation, and binary standardized differences were used for dichotomous variables. Hyperuricemia was analyzed as the primary binary outcome using modified Poisson regression with a log link and HC0 robust sandwich variance; results were expressed as prevalence ratios (PRs) and 95% confidence intervals (CIs). Logistic regression was retained as a supplementary sensitivity analysis, with results expressed as odds ratios (ORs). Continuous serum uric acid was analyzed using ordinary least-squares linear regression, with HC3 heteroscedasticity-robust standard errors used for CIs and p values. β represents the adjusted mean difference in serum uric acid associated with H. pylori positivity compared with H. pylori negativity. Sequential Models 1–4 were used to evaluate progressive attenuation and were not an automated stepwise variable-selection procedure. Model 1 was unadjusted. Model 2 was adjusted for age, sex, and BMI. Model 3 was further adjusted for systolic blood pressure, fasting blood glucose, triglycerides, and HDL-C. Model 4 was the extended clinical model and was further adjusted for eGFR, ALT, GGT, and WBC. Additional sensitivity analyses were conducted to examine model assumptions, including a 4-knot all-continuous restricted cubic spline analysis using the 5th, 35th, 65th, and 95th percentiles; a 3-knot placement sensitivity analysis using the 10th, 50th, and 90th percentiles; and joint log transformation of FBG, TG, ALT, and GGT. These additional analyses were not selected according to statistical significance. The alpha level for statistical significance was 0.05. Sex-stratified analyses were performed to evaluate the associations of H. pylori infection with hyperuricemia and continuous serum uric acid levels separately in men and women. Sex-stratified models were adjusted for age, BMI, systolic blood pressure, fasting blood glucose, triglycerides, HDL-C, eGFR, ALT, GGT, and WBC. To formally assess sex interaction, full-population models including H. pylori infection, sex, an H. pylori infection × sex interaction term, and the same covariates were fitted. Robustness analyses included: (1) replacing eGFR with serum creatinine; (2) repeating the analyses after excluding participants with eGFR < 60 mL/min/1.73 m²; (3) repeating the analyses after excluding participants with serum uric acid values below the 1st percentile or above the 99th percentile; and (4) additionally adjusting for hs-CRP in the hs-CRP complete-case subset. WBC was retained in the primary model as a widely available inflammation-related marker, whereas hs-CRP was evaluated in a sensitivity analysis. Outliers in serum uric acid were not removed from the primary analysis; their influence was evaluated by excluding values outside the 1st to 99th percentiles in sensitivity analysis. To assess multicollinearity among covariates in the extended clinical model, variance inflation factors (VIFs) were calculated. A VIF value <5 was considered to indicate no substantial multicollinearity. Interaction by sex was assessed using a multiplicative H. pylori infection × sex term in full-population models. All statistical tests were two-sided, and p < 0.05 was considered statistically significant. Exact p values were reported when p ≥ 0.001, whereas smaller values were reported as p < 0.001. No correction for multiple comparisons was applied because the analyses addressed the two study outcomes and model-assumption sensitivity rather than screening a large set of unrelated hypotheses. Analyses were performed using Python 3.13.9 with pandas 2.3.3, NumPy 2.3.5, SciPy 1.16.3, statsmodels 0.14.5, and patsy 1.0.1. Modified Poisson models were fitted using statsmodels generalized linear models with a Poisson family, log link, and HC0 robust covariance. Continuous-outcome models were fitted using ordinary least-squares regression with HC3 heteroscedasticity-robust covariance. Restricted cubic splines were constructed using patsy. Complete regression results and supporting sensitivity analyses are provided in the Supporting Information. 2.8. Handling of Missing Data Missing data were evaluated separately in the deduplicated population, the baseline eligible population, and the model-specific analysis populations. Among the 72,392 baseline eligible participants, 4,566 (6.31%) had missing BMI; no participants had missing age or sex at this stage. These participants were excluded, leaving 67,826 participants for the main regression population. Each regression model used complete cases for the variables included in that model. Additional missingness in Model 3 covariates reduced the sample size to 67,540, and additional missingness in Model 4 covariates reduced it to 67,522. Variable-level missingness is reported in S2 Table. hs-CRP measurements were available for 25,928 of 67,826 participants (38.23%) in the main regression population. Because of substantial missingness, hs-CRP was not included in primary models. The hs-CRP sensitivity analysis compared the fully adjusted Model 4 with and without hs-CRP in the same fixed complete-case subset, which included 25,828 participants. 3. Results 3.1. Baseline characteristics of the study population Fig 1 summarizes participant selection. Of 109,329 health examination records initially identified, 106,345 were within the study period. One non-qualifying examination record with essentially unavailable examination measurements was excluded before participant-level deduplication, leaving 106,344 valid study-period records. After retaining only the most recent valid examination for participants with repeated records, 97,378 unique participants remained. Sequentially excluding 24,811 participants with missing H. pylori test results and 175 participants with missing serum uric acid measurements yielded a baseline population of 72,392. Exclusion of 4,566 participants with missing BMI yielded the main regression population of 67,826. Among the baseline population presented in Table 1, 61,739 participants were H. pylori negative and 10,653 were H. pylori positive. Compared with H. pylori-negative participants, H. pylori-positive participants had a higher proportion of men (68.3% vs 60.2%, p < 0.001) and higher BMI, waist circumference, systolic blood pressure, and diastolic blood pressure (all p < 0.001). 10.1371/journal.pone.0358039.t001Table 1Baseline characteristics by H. pylori infection status.VariableH. pylori negative(n = 61,739)H. pylori positive(n = 10,653)SMDp valueAge, years44.79 ± 11.8245.73 ± 11.700.080<0.001Male sex, n (%)37,189 (60.2%)7,279 (68.3%)0.169<0.001BMI, kg/m²24.56 ± 3.5225.34 ± 3.700.220<0.001Waist circumference, cm82.31 ± 11.2784.90 ± 10.720.232<0.001SBP, mmHg119.88 ± 15.38122.60 ± 16.220.175<0.001DBP, mmHg73.27 ± 10.6075.18 ± 11.240.179<0.001Uric acid, μmol/L334.08 ± 82.45349.94 ± 84.990.191<0.001Hyperuricemia10,776 (17.5%)2,352 (22.1%)0.116<0.001FBG, mmol/L5.37 ± 0.945.56 ± 1.290.191<0.001HbA1c, %5.42 ± 0.655.55 ± 0.870.189<0.001TG, mmol/L1.16 [0.82, 1.73]1.32 [0.90, 2.01]0.161<0.001TC, mmol/L4.87 ± 0.924.97 ± 0.970.107<0.001HDL-C, mmol/L1.36 ± 0.371.29 ± 0.360.176<0.001LDL-C, mmol/L3.09 ± 0.823.17 ± 0.860.105<0.001ALT, U/L18.00 [12.00, 27.00]19.00 [13.00, 29.00]0.107<0.001AST, U/L19.64 ± 11.6720.41 ± 11.310.066<0.001GGT, U/L21.00 [14.00, 34.00]24.00 [15.00, 40.00]0.174<0.001Creatinine, μmol/L75.78 ± 17.2578.30 ± 26.780.132<0.001eGFR, mL/min/1.73 m²101.29 ± 13.8499.79 ± 14.310.108<0.001eGFR < 60336 (0.5%)87 (0.8%)0.033<0.001BUN, mmol/L5.47 ± 1.285.49 ± 1.360.0180.107WBC, 10⁹/L6.14 ± 1.536.56 ± 1.660.270<0.001Hemoglobin, g/L144.58 ± 15.41146.90 ± 15.910.150<0.001hs-CRP, mg/L0.74 [0.36, 1.62]0.85 [0.40, 1.95]0.086<0.001Hcy, μmol/L11.10 [9.50, 12.90]11.70 [10.00, 13.80]0.180<0.001Note: Values are presented as mean ± SD, median [Q1, Q3], or n (%), as appropriate. Absolute standardized mean differences are shown. For continuous variables, SMDs were calculated as the difference in group means divided by the pooled standard deviation; binary standardized differences were used for dichotomous variables. Variable-specific denominators were used where measurements were missing. p values were calculated using Welch’s t test, the Mann–Whitney U test, or the chi-square test, as appropriate. hs-CRP was available only in a subset of participants. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; HbA1c, glycated hemoglobin; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; BUN, blood urea nitrogen; WBC, white blood cell count; hs-CRP, high-sensitivity C-reactive protein; Hcy, homocysteine. Baseline characteristics by H. pylori infection status. Note: Values are presented as mean ± SD, median [Q1, Q3], or n (%), as appropriate. Absolute standardized mean differences are shown. For continuous variables, SMDs were calculated as the difference in group means divided by the pooled standard deviation; binary standardized differences were used for dichotomous variables. Variable-specific denominators were used where measurements were missing. p values were calculated using Welch’s t test, the Mann–Whitney U test, or the chi-square test, as appropriate. hs-CRP was available only in a subset of participants. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; HbA1c, glycated hemoglobin; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; BUN, blood urea nitrogen; WBC, white blood cell count; hs-CRP, high-sensitivity C-reactive protein; Hcy, homocysteine. H. pylori-positive participants also had higher serum uric acid levels than H. pylori-negative participants (349.94 ± 84.99 vs 334.08 ± 82.45 μmol/L, p < 0.001), as well as a higher prevalence of hyperuricemia (22.1% vs 17.5%, p < 0.001). In addition, H. pylori-positive participants showed higher fasting blood glucose, HbA1c, triglycerides, ALT, GGT, creatinine, WBC, hs-CRP, and homocysteine levels, whereas HDL-C and eGFR levels were lower (all p < 0.001). 3.2. Association Between H. pylori Infection and Hyperuricemia In the main analysis population, the prevalence of hyperuricemia was higher among H. pylori-positive participants than among H. pylori-negative participants (22.23% vs 17.49%, p < 0.001). In the unadjusted modified Poisson model, H. pylori infection was associated with higher prevalence of hyperuricemia (PR = 1.27, 95% CI: 1.22–1.32, p < 0.001). After adjustment for age, sex, and BMI, the association was attenuated but remained statistically significant (PR = 1.09, 95% CI: 1.05–1.13, p < 0.001). Further adjustment for systolic blood pressure, fasting blood glucose, triglycerides, and HDL-C led to additional attenuation (PR = 1.06, 95% CI: 1.02–1.11, p = 0.002). In the extended clinical model, which additionally included eGFR, ALT, GGT, and WBC, the association was small and the confidence interval included the null (PR = 1.02, 95% CI: 0.98–1.06, p = 0.269). Progressive attenuation therefore remained evident across the sequential models. The corresponding model estimates are shown in Table 2. 10.1371/journal.pone.0358039.t002Table 2Association between H. pylori infection and hyperuricemia estimated using modified Poisson regression with robust variance.ModelAdjustmentNPR95% CIp valueModel 1Unadjusted67,8261.271.22–1.32<0.001Model 2Age, sex, BMI67,8261.091.05–1.13<0.001Model 3Model 2 + SBP, FBG, TG, HDL-C67,5401.061.02–1.110.002Model 4Model 3 + eGFR, ALT, GGT, WBC67,5221.020.98–1.060.269Note: Model 1 was unadjusted. Model 2 was adjusted for age, sex, and BMI. Model 3 was further adjusted for systolic blood pressure, fasting blood glucose, triglycerides, and HDL-C. Model 4 was the extended clinical model and was further adjusted for eGFR, ALT, GGT, and WBC. PRs were estimated using modified Poisson regression with a log link and HC0 robust sandwich variance. PR, prevalence ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; FBG, fasting blood glucose; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; WBC, white blood cell count. Association between H. pylori infection and hyperuricemia estimated using modified Poisson regression with robust variance. Note: Model 1 was unadjusted. Model 2 was adjusted for age, sex, and BMI. Model 3 was further adjusted for systolic blood pressure, fasting blood glucose, triglycerides, and HDL-C. Model 4 was the extended clinical model and was further adjusted for eGFR, ALT, GGT, and WBC. PRs were estimated using modified Poisson regression with a log link and HC0 robust sandwich variance. PR, prevalence ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; FBG, fasting blood glucose; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; WBC, white blood cell count. These findings indicate that the crude cross-sectional association was progressively attenuated after adjustment for measured metabolic, renal, hepatic, and inflammatory factors; the fully adjusted estimate should be interpreted as small and model-dependent rather than as evidence of a causal relationship. 3.3. Association Between H. pylori Infection and Continuous Serum Uric Acid Levels In the analysis of continuous serum uric acid, H. pylori-positive participants had higher mean serum uric acid levels than H. pylori-negative participants (350.76 ± 84.86 vs 334.62 ± 82.46 μmol/L, p < 0.001). In the unadjusted linear regression model, H. pylori positivity was associated with a 16.14 μmol/L higher serum uric acid level (95% CI: 14.34–17.94, p < 0.001). After adjustment for age, sex, and BMI, the difference was substantially reduced (β = 4.37 μmol/L, 95% CI: 2.95–5.80, p < 0.001). Further adjustment for blood pressure, glucose metabolism, and lipid metabolism yielded a β coefficient of 3.70 μmol/L (95% CI: 2.30–5.09, p < 0.001). In the extended clinical model, which additionally included eGFR, ALT, GGT, and WBC, H. pylori positivity remained associated with a modest increase in serum uric acid level (β = 2.14 μmol/L, 95% CI: 0.80–3.49, p = 0.002). Although the fully adjusted association was statistically detectable, the effect magnitude was small and of limited clinical relevance. Detailed continuous-outcome estimates are presented in Table 3. 10.1371/journal.pone.0358039.t003Table 3Association between H. pylori infection and serum uric acid levels estimated using OLS with HC3 robust inference.ModelAdjustmentNβ (μmol/L)95% CIp valueModel 1Unadjusted67,82616.1414.34–17.94<0.001Model 2Age, sex, BMI67,8264.372.95–5.80<0.001Model 3Model 2 + SBP, FBG, TG, HDL-C67,5403.702.30–5.09<0.001Model 4Model 3 + eGFR, ALT, GGT, WBC67,5222.140.80–3.490.002Note: Model 1 was unadjusted. Model 2 was adjusted for age, sex, and BMI. Model 3 was further adjusted for systolic blood pressure, fasting blood glucose, triglycerides, and HDL-C. Model 4 was the extended clinical model and was further adjusted for eGFR, ALT, GGT, and WBC. β coefficients represent the adjusted mean difference in serum uric acid associated with H. pylori positivity. 95% CIs and p values were calculated using HC3 heteroscedasticity-robust standard errors. CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; FBG, fasting blood glucose; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; WBC, white blood cell count. Association between H. pylori infection and serum uric acid levels estimated using OLS with HC3 robust inference. Note: Model 1 was unadjusted. Model 2 was adjusted for age, sex, and BMI. Model 3 was further adjusted for systolic blood pressure, fasting blood glucose, triglycerides, and HDL-C. Model 4 was the extended clinical model and was further adjusted for eGFR, ALT, GGT, and WBC. β coefficients represent the adjusted mean difference in serum uric acid associated with H. pylori positivity. 95% CIs and p values were calculated using HC3 heteroscedasticity-robust standard errors. CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; FBG, fasting blood glucose; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; WBC, white blood cell count. 3.4. Sex-Stratified and Interaction Analyses In the sex-stratified analyses, the prevalence of hyperuricemia was higher among H. pylori-positive than H. pylori-negative participants in both men (28.17% vs 24.25%) and women (8.92% vs 6.96%). Among men, the HUA PR was 1.10 (95% CI: 1.06–1.15, p < 0.001) in the basic adjusted model and 1.04 (95% CI: 0.99–1.08, p = 0.087) in the extended clinical model. Among women, the corresponding PRs were 1.02 (95% CI: 0.90–1.15, p = 0.794) and 0.96 (95% CI: 0.85–1.08, p = 0.509). The H. pylori infection × sex interaction was not statistically significant (p = 0.110). For continuous serum uric acid levels, the extended clinical β was 2.60 μmol/L among men (95% CI: 0.86–4.35, p = 0.004) and 1.33 μmol/L among women (95% CI: −0.59–3.26, p = 0.174). The H. pylori infection × sex interaction was not statistically significant (p = 0.765). Overall, although the association appeared slightly stronger in men, formal interaction tests did not support sex-specific heterogeneity in the associations of H. pylori infection with either hyperuricemia or serum uric acid levels. Sex-stratified results are summarized in Table 4. 10.1371/journal.pone.0358039.t004Table 4Sex-stratified associations of H. pylori infection with hyperuricemia and serum uric acid levels.Panel A. HyperuricemiaSexModelNPR95% CIp valueMaleBasic adjusted model42,1291.101.06–1.15<0.001MaleExtended clinical model41,9331.040.99–1.080.087FemaleBasic adjusted model25,6971.020.90–1.150.794FemaleExtended clinical model25,5890.960.85–1.080.509P for H. pylori × sex interaction0.110 Panel B. Serum uric acid Sex Model N β (μmol/L) 95% CI p value MaleBasic adjusted model42,1295.233.38–7.08<0.001MaleExtended clinical model41,9332.600.86–4.350.004FemaleBasic adjusted model25,6972.880.84–4.930.006FemaleExtended clinical model25,5891.33−0.59–3.260.174P for H. pylori × sex interaction0.765Note: Table 4 presents two vertically arranged panels. Panel A reports PRs from modified Poisson regression with HC0 robust sandwich variance; Panel B reports β coefficients from OLS with HC3 heteroscedasticity-robust standard errors. Sex-stratified models were adjusted for age, BMI, SBP, FBG, TG, HDL-C, eGFR, ALT, GGT, and WBC. p values for interaction were estimated from full-population models including the H. pylori infection × sex term. CI, confidence interval; HUA, hyperuricemia; UA, uric acid; PR, prevalence ratio; BMI, body mass index; SBP, systolic blood pressure; FBG, fasting blood glucose; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; WBC, white blood cell count. Sex-stratified associations of H. pylori infection with hyperuricemia and serum uric acid levels. Note: Table 4 presents two vertically arranged panels. Panel A reports PRs from modified Poisson regression with HC0 robust sandwich variance; Panel B reports β coefficients from OLS with HC3 heteroscedasticity-robust standard errors. Sex-stratified models were adjusted for age, BMI, SBP, FBG, TG, HDL-C, eGFR, ALT, GGT, and WBC. p values for interaction were estimated from full-population models including the H. pylori infection × sex term. CI, confidence interval; HUA, hyperuricemia; UA, uric acid; PR, prevalence ratio; BMI, body mass index; SBP, systolic blood pressure; FBG, fasting blood glucose; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; WBC, white blood cell count. 3.5. Robustness and Supplementary Analyses The robustness analyses were generally consistent with the extended clinical model. For hyperuricemia, the PR was 1.03 (95% CI: 0.99–1.07, p = 0.124) when serum creatinine replaced eGFR, 1.02 (95% CI: 0.98–1.07, p = 0.248) after excluding participants with eGFR < 60 mL/min/1.73 m², and 1.02 (95% CI: 0.98–1.06, p = 0.381) after excluding serum uric acid values outside the 1st–99th percentiles. Within the same hs-CRP complete-case subset (n = 25,828), the HUA estimate was virtually unchanged after addition of hs-CRP (PR approximately 0.990 before and after hs-CRP adjustment), indicating that the difference from the main-population estimate was primarily related to restriction to the hs-CRP-available subset rather than to hs-CRP adjustment itself. Robustness results are presented in Table 5 and S8 Table. 10.1371/journal.pone.0358039.t005Table 5Robustness analyses for the associations of H. pylori infection with hyperuricemia and serum uric acid levels.Panel A. HyperuricemiaAnalysisNPR95% CIp valueCreatinine replacing eGFR67,5221.030.99–1.070.124Exclude eGFR < 6067,1441.020.98–1.070.248Exclude UA outside 1st–99th percentile66,1711.020.98–1.060.381Additional hs-CRP adjustment in hs-CRP complete-case subset25,8280.990.93–1.060.752 Panel B. Continuous serum uric acid Analysis N β (μmol/L) 95% CI p value Creatinine replacing eGFR67,5222.300.94–3.67<0.001Exclude eGFR < 6067,1442.090.74–3.430.002Exclude UA outside 1st–99th percentile66,1711.730.47–2.990.007Additional hs-CRP adjustment in hs-CRP complete-case subset25,8281.68−0.53–3.880.136Note: Table 5 presents two vertically arranged panels. Panel A reports PRs from modified Poisson regression with HC0 robust sandwich variance; Panel B reports β coefficients from OLS with HC3 heteroscedasticity-robust standard errors. The extended clinical model adjusted for age, sex, BMI, SBP, FBG, TG, HDL-C, eGFR, ALT, GGT, and WBC. In the creatinine sensitivity model, eGFR was replaced by serum creatinine. The hs-CRP sensitivity analysis was restricted to 25,828 participants with complete data for hs-CRP and all Model 4 covariates. CI, confidence interval; UA, uric acid; PR, prevalence ratio; BMI, body mass index; SBP, systolic blood pressure; FBG, fasting blood glucose; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; WBC, white blood cell count; hs-CRP, high-sensitivity C-reactive protein. Robustness analyses for the associations of H. pylori infection with hyperuricemia and serum uric acid levels. Note: Table 5 presents two vertically arranged panels. Panel A reports PRs from modified Poisson regression with HC0 robust sandwich variance; Panel B reports β coefficients from OLS with HC3 heteroscedasticity-robust standard errors. The extended clinical model adjusted for age, sex, BMI, SBP, FBG, TG, HDL-C, eGFR, ALT, GGT, and WBC. In the creatinine sensitivity model, eGFR was replaced by serum creatinine. The hs-CRP sensitivity analysis was restricted to 25,828 participants with complete data for hs-CRP and all Model 4 covariates. CI, confidence interval; UA, uric acid; PR, prevalence ratio; BMI, body mass index; SBP, systolic blood pressure; FBG, fasting blood glucose; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; WBC, white blood cell count; hs-CRP, high-sensitivity C-reactive protein. For continuous serum uric acid, the robustness estimates were 2.30 μmol/L (95% CI: 0.94–3.67, p < 0.001) when creatinine replaced eGFR, 2.09 μmol/L (95% CI: 0.74–3.43, p = 0.002) after excluding eGFR < 60 mL/min/1.73 m2, and 1.73 μmol/L (95% CI: 0.47–2.99, p = 0.007) after excluding extreme serum uric acid values. In the hs-CRP complete-case subset, additional adjustment for hs-CRP yielded β = 1.68 μmol/L (95% CI: −0.53–3.88, p = 0.136). Robustness results are presented in Table 5 and S8 Table. In an additional sensitivity analysis, all sequential models were refitted in the same Model 4 complete-case population (n = 67,522). For hyperuricemia, the PR decreased from 1.27 in Model 1 to 1.02 in Model 4, closely matching the estimates obtained from the model-specific complete-case analyses. For continuous serum uric acid, the corresponding β coefficient decreased from approximately 16 to 2.14 μmol/L. Thus, progressive attenuation persisted when the analysis population was held constant (S5 Table). In addition, all covariates in the extended clinical model had VIF values below 2, indicating no substantial multicollinearity. Functional-form sensitivity analyses yielded small HUA effect estimates across specifications. The linear Model 4 PR was 1.022 (95% CI: 0.983–1.064, p = 0.269), the 4-knot RCS sensitivity PR was 1.042 (95% CI: 1.003–1.082, p = 0.033), the 3-knot placement sensitivity PR was 1.044 (95% CI: 1.006–1.084, p = 0.024), and the joint log-transformed sensitivity PR was 1.018 (95% CI: 0.979–1.058, p = 0.371). These additional sensitivity analyses were conducted to examine model assumptions; no specification was selected on the basis of statistical significance. 4. Discussion 4.1. Principal Findings In this large-scale health examination population (N = 67,826), we evaluated the cross-sectional association between H. pylori infection and abnormalities in uric acid metabolism. The crude PR for hyperuricemia was 1.27 and progressively attenuated to 1.02 in the fully adjusted modified Poisson model. The fully adjusted association between H. pylori positivity and hyperuricemia was small. For continuous serum uric acid, H. pylori positivity was associated with a statistically detectable but clinically modest β of 2.14 μmol/L. Sex interaction tests were not statistically significant. Functional-form sensitivity analyses showed that statistical significance for hyperuricemia varied across specifications, although effect estimates remained modest. 4.2. Attenuation after Adjustment for Metabolic, Renal, and Inflammatory Factors In the present study, the apparent association between H. pylori infection and hyperuricemia was progressively attenuated after sequential adjustment. The unadjusted modified Poisson model yielded PR = 1.27, whereas the fully adjusted model yielded PR = 1.02 with a confidence interval including the null. This pattern indicates that the crude cross-sectional association does not necessarily represent an association independent of measured metabolic, renal, hepatic, and inflammatory factors. Rather, both conditions may coexist within a broader clinical context characterized by metabolic abnormalities, altered renal excretion, and low-grade systemic inflammation. Previous studies have suggested potential links between H. pylori infection, insulin resistance, metabolic syndrome, and chronic low-grade inflammation, although the epidemiological evidence remains inconsistent [3]. Some observational studies and systematic reviews have reported that H. pylori-infected individuals are more likely to have metabolic disturbances and insulin resistance, whereas others have emphasized heterogeneity across populations and the influence of confounding factors [3,10,11]. In uric acid metabolism, insulin resistance and hyperinsulinemia may reduce renal uric acid excretion and promote urate reabsorption through effects on renal tubular urate transport [7,8]. These findings are compatible with overlapping metabolic and inflammatory characteristics, but the cross-sectional design cannot distinguish confounding from downstream pathways or establish a causal sequence. The sequential attenuation observed across the model series is consistent with adjustment for measured clinical domains. After systolic blood pressure, fasting blood glucose, triglycerides, and HDL-C were included in Model 3, the HUA PR was substantially attenuated. With additional adjustment for eGFR, ALT, GGT, and WBC in Model 4, the PR was 1.02 and the confidence interval included the null. eGFR, calculated using the 2021 CKD-EPI equation, reflects renal capacity for uric acid clearance and is a relevant correlate of serum uric acid levels [6,13]. ALT and GGT are related to hepatic metabolic status and overall metabolic burden, whereas WBC reflects systemic inflammatory background. Functional-form sensitivity analyses further qualified this interpretation. The HUA PR was 1.022 (95% CI: 0.983–1.064, p = 0.269) in the linear specification, 1.042 (95% CI: 1.003–1.082, p = 0.033) in the 4-knot spline sensitivity analysis, 1.044 (95% CI: 1.006–1.084, p = 0.024) in the 3-knot placement sensitivity analysis, and 1.018 (95% CI: 0.979–1.058, p = 0.371) in the joint log-transformation sensitivity analysis. Effect estimates remained small across specifications, although statistical significance was sensitive to the functional form used for continuous covariates. The corresponding continuous-UA estimates remained approximately 2–3 μmol/L across flexible and transformed specifications. 4.3. Sex-Stratified Findings and Clinical Relevance Sex-stratified estimates were somewhat larger in men, but interaction tests were not statistically significant for either outcome. The fully adjusted difference in continuous serum uric acid among men was 2.60 μmol/L and should be interpreted as clinically modest. These findings should therefore be interpreted cautiously and do not support a clearly sex-specific biological effect. Men generally have higher baseline serum uric acid and hyperuricemia prevalence, potentially reflecting sex-related differences in renal urate handling and estrogen effects [14,15]. These background differences may contribute to the slightly stronger male estimate, but they do not establish sex-specific heterogeneity. 4.4. Strengths and limitations This study has several strengths. First, it was based on a large health examination population, with 67,826 participants included in the main regression analyses, providing substantial statistical power. Second, a strict individual-level deduplication strategy was applied: for participants with multiple examinations during the study period, only the most recent valid examination record was retained, thereby reducing potential bias from repeated measurements. Third, we examined both hyperuricemia as a binary outcome and serum uric acid as a continuous outcome, so the findings did not rely solely on a single diagnostic threshold. Fourth, we used sequential adjustment models incorporating a broad range of objective health examination indicators, including demographic factors, BMI, blood pressure, glucose and lipid metabolism, renal function, liver enzymes, and WBC. Robustness analyses were also performed by replacing eGFR with serum creatinine, excluding participants with eGFR < 60 mL/min/1.73 m2, excluding extreme serum uric acid values, and additionally adjusting for hs-CRP in the hs-CRP-available subset. In addition, all covariates in the extended clinical model had low VIF values, indicating no substantial multicollinearity. Several limitations should also be acknowledged. First, because of the cross-sectional design, H. pylori infection status, serum uric acid levels, and related metabolic indicators were measured at the same health examination. Therefore, temporal relationships could not be established, causal inference is not possible, and the findings should be interpreted as statistical associations rather than causal effects. Second, although multiple objective clinical indicators were adjusted for, residual confounding could not be fully excluded. The health examination database lacked information on several important lifestyle and medication-related factors, including high-purine diet, alcohol intake, particularly beer consumption, smoking, physical activity, and the use of medications that may substantially influence serum uric acid levels, such as diuretics, low-dose aspirin, and urate-lowering agents. Because these factors may be associated with both H. pylori infection and uric acid metabolism, residual confounding cannot be excluded and may have influenced the magnitude of the observed associations. Although our models included several objective clinical indicators related to metabolic and renal status, these variables could not fully replace direct information on lifestyle and medication use. Third, H. pylori infection status was determined using the 13C-urea breath test, which is commonly used to assess current infection. However, the retrospective database did not contain individual-level information on recent proton pump inhibitor, antibiotic, or bismuth use before 13C-UBT. Because these medications may reduce the sensitivity of H. pylori testing, some false-negative results and exposure misclassification cannot be excluded. Data on previous H. pylori infection and eradication history were also unavailable. Fourth, hs-CRP had substantial missingness in this cohort and was therefore not included in the primary models. WBC was retained as an inflammation-related marker in the main model, and hs-CRP was additionally adjusted for only in the available-subset sensitivity analysis. Incomplete control of inflammation and selection bias in the hs-CRP subset remain possible. Fifth, a substantial number of otherwise eligible participants lacked H. pylori test results, and participants entering the baseline analysis differed from excluded participants on several measured characteristics. Selection related to test availability therefore cannot be excluded. A further 4,566 participants were excluded because BMI was missing, and measured characteristics also differed between participants included in and excluded from the main regression population. The analytical database did not contain information on the operational reasons for test availability. Finally, the study population was derived from health examinations. Participants may have had greater health awareness or specific occupational backgrounds compared with the general community population, raising the possibility of a healthy worker effect. Therefore, caution is needed when generalizing these findings to the broader community or to specific clinical patient populations. 5. Conclusion In this large health examination population, any remaining association between H. pylori positivity and hyperuricemia after comprehensive adjustment was small and sensitive to model specification. H. pylori positivity was also associated with a statistically detectable but clinically modest difference in continuous serum uric acid levels. Given the cross-sectional design, these findings should not be interpreted causally. Supporting information Complete regression results for the primary sequential models. (XLSX) Variable-level missingness in the study populations. (XLSX) Comparison of participants included in and excluded from the analysis populations. (XLSX) Logistic-regression sensitivity analysis for hyperuricemia. (XLSX) Same complete-case sequential models. (XLSX) Functional-form sensitivity analyses. (XLSX) Robust Wald tests for nonlinearity of continuous covariates. (XLSX) hs-CRP fixed-subset sensitivity analysis. (XLSX) Linear-model diagnostic and heteroscedasticity summary. (XLSX) 5 Aug 2026 Dear Dr. Fang, The manuscript has been evaluated by two reviewers, and their comments are available below. The reviewers note that a strength of the manuscript is the large sample size; however, they each raise concerns regarding the statistical analyses that must be fully addressed as a prerequisite to further consideration. In addition, the identity of the health examination database must be described in more detail. Could you please carefully revise the manuscript to address all comments raised? Please submit your revised manuscript by Oct 03 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Emily Chenette Editor in Chief PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf. 2. Please note that PLOS One has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, we expect all author-generated code to be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse. 3. Thank you for stating in your Funding Statement: “This work was supported in part by the 2022 National Key Research and Development Program of China, Key Special Project on “Active Health and Science and Technology Response to Population Aging” (No. 2022YFC3600903), entitled “Research on the Construction and Output Technology of Active Health Knowledge System.” The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. “ Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now. Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement. Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf. 4. In the online submission form, you indicated that your data is available only on request from a third party. Please note that your Data Availability Statement is currently missing [the name of the third party contact or institution / contact details for the third party, such as an email address or a link to where data requests can be made]. Please update your statement with the missing information. 5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. 6. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 2-5 in your text; if accepted, production will need this reference to link the reader to the Table. 7. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Additional Editor Comments (if provided): 1) As you revise your manuscript to address the reviewers' comments, please include in the Methods a description of the health examination database used in this research. If, for example, the database is composed of patient records from Shanghai Health and Medical Center (or another hospital or clinic), please state this in the Methods. If the study used third-party data (for example, the National Health and Nutrition Examination Survey (NHANES)) this also needs to be clearly indicated in the Methods. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: No Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: Thank you for the opportunity to review this manuscript. This is a well-conducted study with a large sample size and appropriate statistical analyses. The manuscript is generally well written, and the conclusions are supported by the results. I have a few suggestions that may improve the manuscript. 1- Please expand the discussion on residual confounding, especially because information on smoking, alcohol use, diet, physical activity, and medications was not available. 2- The association found after adjustment is statistically significant but very small. Please emphasize that the clinical significance of this finding may be limited. 3- Please provide a reference for the definition of hyperuricemia used in the study. 4- Please check the manuscript for small inconsistencies in percentages and table formatting. 5- Please ensure that the manuscript includes a clear Data Availability Statement in accordance with PLOS ONE requirements. Overall, I believe the manuscript is scientifically sound and would be suitable for publication after these minor revisions. Reviewer #2: Overall assessment This manuscript evaluates the cross-sectional association between Helicobacter pylori infection, hyperuricemia, and serum uric acid levels in a large health examination population. The large sample size, use of the ^13C-urea breath test, sequential regression models, sex-stratified analyses, and sensitivity analyses are important strengths. The main finding is that the crude association between H. pylori positivity and hyperuricemia becomes non-significant after adjustment for metabolic, renal, hepatic, and inflammation-related variables. A small association with continuous serum uric acid remains, but its magnitude is unlikely to be clinically relevant. The study is potentially valuable, but several methodological and interpretative issues should be addressed. I recommend major revision. Major comments 1. Interpretation of sequential adjustment The authors frequently state that metabolic, renal, hepatic, and inflammatory factors “explain” the association. However, attenuation after adjustment in a cross-sectional analysis does not establish mediation or causality. Some adjusted variables may be confounders, whereas others could potentially lie on the pathway between infection and uric acid metabolism. The authors should clarify the purpose of each model and replace causal wording such as “explained by” with more cautious language, for example: “The association was substantially attenuated after adjustment for measured metabolic, renal, hepatic, and inflammation-related variables.” The proposed “shared metabolic-inflammatory phenotype” should be presented as a possible interpretation rather than a demonstrated mechanism. 2. Participant selection and missing data The cohort decreased from 97,379 unique participants to 72,392 participants with valid H. pylori and uric acid data and then to 67,827 participants in the regression analyses. The authors should provide a participant flow diagram and clarify: whether the ^13C-urea breath test was routine or optional; why such a large number of participants lacked relevant measurements; whether included and excluded participants differed; and whether selection for H. pylori testing could have introduced bias. The statement that missingness was below 1% for core covariates appears inconsistent with the exclusion of 4,565 participants after the baseline analysis. A table reporting missing data for each variable is required. Sequential models should also be repeated in the same complete-case population to ensure that attenuation is not partly caused by changing sample sizes. 3. Description of the ^13C-urea breath test The test protocol is insufficiently described. The Methods should include: manufacturer and analytical system; administered ^13C-urea dose; timing of breath samples; positivity threshold; fasting requirements; quality-control procedures; and required withdrawal periods for proton pump inhibitors, antibiotics, and bismuth compounds. The potential influence of recent treatment on false-negative results should be discussed. 4. Laboratory methods The manuscript should provide details regarding the measurement of serum uric acid, creatinine, glucose, lipids, liver enzymes, WBC, and hs-CRP, including analytical methods, equipment, reagents, fasting conditions, and quality control. The sex-specific hyperuricemia thresholds of >420 μmol/L in men and >360 μmol/L in women should be supported by an appropriate reference. 5. Covariate selection The rationale for including some variables and excluding others is unclear. For example, the model includes BMI but not waist circumference, systolic but not diastolic blood pressure, fasting glucose but not HbA1c, and ALT and GGT but not AST. The authors should explain whether covariates were selected based on prior evidence, a causal framework, data availability, or statistical criteria. They should also clarify whether the analysis plan was established before inspecting the results. 6. Statistical analysis Because this is a cross-sectional study, the manuscript should refer to prevalence or prevalence odds rather than “risk.” Since hyperuricemia prevalence is relatively high, adjusted prevalence ratios obtained using Poisson regression with robust variance may be easier to interpret than odds ratios. The authors should also: evaluate non-linear relationships of continuous covariates; assess residuals and heteroscedasticity in linear regression; consider transformations for skewed variables; and report the exact software packages and functions used. The statement that regression estimates were generated using “matrix-based” routines is not sufficiently reproducible. The analyses should preferably be validated using established statistical software, and the code should be made available. 7. Clinical relevance and hs-CRP analysis The fully adjusted increase in serum uric acid was only 2.14 μmol/L, indicating very limited clinical relevance. This should remain central to the interpretation. Moreover, after additional adjustment for hs-CRP, the association with continuous serum uric acid was no longer statistically significant. This result should be discussed more clearly. It may reflect additional inflammatory adjustment, reduced statistical power, selection bias in the hs-CRP subset, or a combination of these factors. 8. Conclusions The conclusion should be more cautious. The study supports substantial attenuation after adjustment but does not establish that H. pylori and hyperuricemia share a specific biological phenotype. A more appropriate conclusion would be: In this cross-sectional health examination population, the crude association between H. pylori positivity and hyperuricemia was substantially attenuated after adjustment for measured metabolic, renal, hepatic, and inflammation-related variables. A small adjusted difference in continuous serum uric acid remained, but its clinical relevance was limited. Longitudinal and eradication-based studies are required to clarify temporality and potential mechanisms. Minor comments Replace “risk” with “prevalence,” “prevalence odds,” or “cross-sectional association.” Use eGFR, not EGFR, consistently. Add a participant flow diagram. Report standardized differences in Table 1, as very small differences may produce P<0.001 in such a large cohort. Clarify the sample size and denominator for each analysis. Report the number and percentage of participants with available hs-CRP data. Clarify whether participants using urate-lowering medication, diuretics, antibiotics, proton pump inhibitors, or bismuth were included. Shorten the Discussion, particularly the repetitive interpretation of model attenuation. Expand the literature concerning previous studies of H. pylori, hyperuricemia, and gout. The manuscript would benefit from careful English-language editing. Recommendation The study addresses an interesting question and benefits from a large sample size. However, participant selection, missing data, laboratory methods, statistical reproducibility, and interpretation of adjusted associations require clarification. Recommendation: Major Revision ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Zean Zefenkey Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 14 Aug 2026 A detailed point-by-point response to all editor and reviewer comments has been uploaded as a separate “Response to Reviewers” file. All comments have been addressed, and the corresponding revisions are shown in the marked-up manuscript. Submitted filename: PONE-D-26-26394_RESPONSE_TO_REVIEWERS_FINAL_FORMATTED.docx 26 Aug 2026 Helicobacter pylori infection, hyperuricemia, and serum uric acid levels: the role of metabolic, renal, and inflammatory factors in a large health examination population PONE-D-26-26394R1 Dear Dr. Fang, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Ahmed E. Abdel Moneim Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: (No Response) Reviewer #2: The authors have carefully addressed the comments raised during the previous review, and the revised manuscript has been substantially improved, particularly with regard to the statistical analyses, methodological description, and interpretation of the findings. The major concerns have been adequately resolved. I noted only a few very minor editorial inconsistencies in the revised/marked-up version, mainly related to sample-size notation, table numbering, and wording in table notes. These should be corrected during final proofreading. Overall, I consider the manuscript suitable for publication in PLOS ONE after these minor editorial corrections. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: No ********** PONE-D-26-26394R1 PLOS One Dear Dr. Fang, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS One and supporting open access. Kind regards, PLOS One Editorial Office Staff on behalf of Dr. Ahmed E. Abdel Moneim Academic Editor PLOS One